We are excited to share Tracells' latest research, presented at ECCO 2025, showcasing the potential of fecal host transcriptomics as a game-changing tool for IBD management. Our study demonstrates that by analyzing epithelial and immune cell transcripts shed into stool, we can accurately assess intestinal inflammation, disease severity, and localization—all from a simple stool sample collected at home.
This breakthrough could significantly improve patient care by enabling real-time, non-invasive disease monitoring, helping clinicians make more informed treatment decisions, and ultimately reducing the burden on healthcare systems. With the potential to replace or complement invasive procedures, this approach offers a scalable and patient-friendly solution for managing inflammatory bowel diseases.
Less than a year since transitioning out of academia, this technology is already being refined and optimized for clinical application—reflecting Tracells' commitment to transforming cutting-edge science into real-world solutions. We are dedicated to making smarter, more efficient disease monitoring tools accessible to both patients and healthcare providers.
We deeply appreciate the dedication and hard work of the entire Tracells team in bringing this research to life. A heartfelt thank you to our collaborators from the gastroenterology departments at Soroka and Sheba Medical Centers—your contributions have been invaluable in advancing this important work.
Our CEO recently shared insights on this exciting work and its potential impact—read more here.
Check out the post below and stay tuned as we continue to innovate in precision diagnostics for gastroenterology. We value your insights and encourage you to share your comments and feedback with us.
